Proportion, Histopathological Spectrum, and Clinicopathological Characteristics of Soft Tissue Sarcomas in Cameroon: A Sixteen-Year Retrospective Registry-Based Study

This is the authors' abstract. We don't add key points for this paper.

BackgroundSoft tissue sarcomas (STSs) are a heterogeneous group of rare malignant mesenchymal neoplasms.1–3 Their marked histological diversity, variable anatomical presentation, and nonspecific clinical features frequently contribute to delayed diagnosis and suboptimal management, particularly in low- and middle-income countries where population-based epidemiological data remain limited.1–4 This study aimed to determine the prevalence and clinicopathological characteristics of soft tissue sarcomas using data from the Yaoundé Cancer Registry over a fifteen-year period in Cameroon. MethodA retrospective descriptive study was conducted using data extracted from the Yaoundé Cancer Registry between 2005 and 2020. Demographic variables, histopathological subtype, anatomical site, diagnostic method, and extent of disease at diagnosis were extracted using a standardized data collection tool. Data were analyzed using SPSS version 26. Descriptive statistics were used to summarize patient and tumor characteristics.ResultsAmong 12,386 registered cancer cases, 217 were diagnosed as soft tissue sarcomas, corresponding to a prevalence of 1.7%. Seventeen histopathological subtypes were identified. Rhabdomyosarcoma was the most common subtype (23.5%), followed by Kaposi sarcoma (16.6%) and fibrosarcoma (14.7%). Carcinosarcoma, gastrointestinal stromal tumor, and invasive cystosarcoma phyllodes each accounted for 0.5% of cases. The lower extremities and hip region represented the most frequent anatomical site of disease, whereas retroperitoneal tumors were uncommon. Most patients presented with localized disease (32.3%) at diagnosis, and males were more frequently affected than females.ConclusionsThese findings provide important baseline epidemiological data for Cameroon and underscore the need for improved diagnostic capacity, multidisciplinary sarcoma management, and strengthened national cancer surveillance to facilitate earlier diagnosis.